Efficacy and Safety Study of DURVALUMAB Maintenance in Patients With Stage III Non-Small Cell Lung Cancer
Active, not recruiting
- Conditions
- Bronchial Cancer
- Registration Number
- NCT06564870
- Lead Sponsor
- University Hospital, Brest
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Active, not recruiting
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Inclusion Criteria:<br><br> - Patients with unresectable locally advanced non-small-cell lung cancer (stages II,<br> IIIA, IIIB and IIIC) responding to or stable after concomitant or sequential<br> platinum-based radiochemotherapy and having received durvalumab consolidation<br> therapy<br><br> - Minimum radiotherapy dose of 54 Gy to 66 Gy<br><br> - Age greater than or equal to 18 years<br><br> - WHO 0-1<br><br> - Non-opposition of living patients formulated<br><br>Exclusion Criteria:<br><br> - Age < 18 years.<br><br> - Refusal to participate<br><br> - Patients under legal protection (curatorship, guardianship, etc.)
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Real-life efficacy of durvalumab treatment in maintenance after chemoradiotherapy.
- Secondary Outcome Measures
Name Time Method